TXA Nebulization for the Treatment of Hemoptysis

Launched by POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH · Dec 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid (TXA) delivered through a nebulizer to help treat hemoptysis, which is when a person coughs up blood. The goal is to see if nebulized TXA can reduce how often and how much blood is coughed up, as well as to evaluate its safety in patients experiencing this condition. The trial is currently recruiting participants who are at least 18 years old and have active hemoptysis, regardless of gender. However, individuals with severe bleeding, certain medical conditions like kidney failure, or those who are pregnant are not eligible to participate.

Participants in this study can expect to receive the nebulized TXA treatment and will be monitored for its effectiveness and any potential side effects. This trial aims to gather more information about the benefits and safety of using TXA in this new way, as there is still limited research on this approach. Your involvement could contribute to better treatment options for people with hemoptysis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All cases of active hemoptysis
• • irrespective of gender
• • age≥ 18 years
• Exclusion Criteria:
• • Massive hemoptysis
• • Pregnancy
• • Drug allergy to TXA4
• • Renal failure
• • Receiving Oral Contraceptive Pills.
• • Already on blood thinner
• • Not willing for consent.